AU7227387A - Production of polyalkylene oxides with zinc catalyst - Google Patents

Production of polyalkylene oxides with zinc catalyst

Info

Publication number
AU7227387A
AU7227387A AU72273/87A AU7227387A AU7227387A AU 7227387 A AU7227387 A AU 7227387A AU 72273/87 A AU72273/87 A AU 72273/87A AU 7227387 A AU7227387 A AU 7227387A AU 7227387 A AU7227387 A AU 7227387A
Authority
AU
Australia
Prior art keywords
production
polyalkylene oxides
zinc catalyst
zinc
catalyst
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU72273/87A
Other languages
English (en)
Inventor
Walter Thomas Reichle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Union Carbide Corp
Original Assignee
Union Carbide Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Union Carbide Corp filed Critical Union Carbide Corp
Publication of AU7227387A publication Critical patent/AU7227387A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2642—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds characterised by the catalyst used
    • C08G65/269—Mixed catalyst systems, i.e. containing more than one reactive component or catalysts formed in-situ
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/04—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers only
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/04—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers only
    • C08G65/06—Cyclic ethers having no atoms other than carbon and hydrogen outside the ring
    • C08G65/08—Saturated oxiranes
    • C08G65/10—Saturated oxiranes characterised by the catalysts used
    • C08G65/12—Saturated oxiranes characterised by the catalysts used containing organo-metallic compounds or metal hydrides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Polyethers (AREA)
AU72273/87A 1986-05-02 1987-04-30 Production of polyalkylene oxides with zinc catalyst Abandoned AU7227387A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/858,914 US4667013A (en) 1986-05-02 1986-05-02 Process for alkylene oxide polymerization
US858914 1986-05-02

Publications (1)

Publication Number Publication Date
AU7227387A true AU7227387A (en) 1987-11-05

Family

ID=25329489

Family Applications (1)

Application Number Title Priority Date Filing Date
AU72273/87A Abandoned AU7227387A (en) 1986-05-02 1987-04-30 Production of polyalkylene oxides with zinc catalyst

Country Status (6)

Country Link
US (1) US4667013A (enExample)
EP (1) EP0243969A3 (enExample)
JP (1) JPS62273227A (enExample)
AU (1) AU7227387A (enExample)
BR (1) BR8702151A (enExample)
CA (1) CA1279435C (enExample)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69910931T2 (de) * 1998-04-03 2004-07-22 Nippon Shokubai Co. Ltd. Verfahren zur herstellung von feinen organometallischen teilchen und polymerisationskatalysator
AU5731000A (en) * 1999-06-11 2001-01-02 Procter & Gamble Company, The Soluble polyfunctional initiators for lactone ring-opening polymerization
RU2165438C1 (ru) * 1999-12-14 2001-04-20 Открытое акционерное общество "Нижнекамскнефтехим" Способ управления процессом получения оксиэтилированных алкилфенолов
AU2001255437A1 (en) 2000-09-12 2002-03-26 Union Carbide Chemicals And Plastics Polymer composites containing alkylene oxide copolymers
CA2483656C (en) * 2002-04-29 2013-06-18 Alza Corporation Reduced formate poly(alkylene oxide) for a controlled release dosage form of reboxetine
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DK1658054T3 (da) * 2003-08-06 2007-10-01 Gruenenthal Gmbh Indgivelsesform, som er sikret mod misbrug
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
EP2338994B1 (en) 2004-09-02 2014-03-19 Yale University Regulation of oncogenes by microRNAs
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2007002528A1 (en) * 2005-06-23 2007-01-04 Yale University Anti-aging micrornas
US8658608B2 (en) * 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
WO2008086529A2 (en) * 2007-01-11 2008-07-17 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US20100111943A1 (en) * 2007-03-22 2010-05-06 Medical College Of Georgia Research Institute, Inc Compositions and methods for inhibiting cancer metastasis
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
WO2009111375A2 (en) * 2008-03-01 2009-09-11 Abraxis Bioscience, Llc Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
AU2009244267A1 (en) * 2008-05-07 2009-11-12 Abraxis Bioscience, Llc Enhancement of drug therapy by miRNA
BRPI0912014A2 (pt) 2008-05-09 2019-03-06 Grünenthal GmbH processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob uso de uma etapa de congelamento por atomização
KR20110123252A (ko) * 2009-02-11 2011-11-14 다우 글로벌 테크놀로지스 엘엘씨 연성 중합체 결합제 및 이를 사용하는 배터리 구성요소
US8309356B2 (en) * 2009-04-01 2012-11-13 Yale University Pseudocomplementary oligonucleotides for targeted gene therapy
RU2015138422A (ru) 2009-07-22 2018-12-25 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
CN102573805A (zh) * 2009-07-22 2012-07-11 格吕伦塔尔有限公司 热熔挤出的控制释放剂型
EP2287304A1 (en) 2009-08-17 2011-02-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel treatment of patients after stent implantation or balloon dilatation and novel drug eluting stents
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
US20110293585A1 (en) 2010-04-21 2011-12-01 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
US20110262406A1 (en) 2010-04-21 2011-10-27 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
BR112013005234A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo um polímero aniônico.
NZ607392A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising inorganic salt
US8459326B2 (en) * 2011-01-06 2013-06-11 Hunter Douglas, Inc. Cellular shade assembly and method for constructing same
WO2012106591A1 (en) 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-34
JP2014506789A (ja) 2011-02-03 2014-03-20 マーナ セラピューティクス インコーポレイテッド ｍｉＲ−１２４の合成模倣体
JP5927184B2 (ja) * 2011-06-03 2016-06-01 住友精化株式会社 ポリアルキレンオキシド粒子及びその製造方法
KR101907233B1 (ko) * 2011-06-03 2018-10-11 스미토모 세이카 가부시키가이샤 폴리알킬렌옥시드 입자 및 그의 제조방법
RS56527B1 (sr) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
PE20141638A1 (es) 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
EP2739734A1 (en) 2011-08-03 2014-06-11 The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System Treatment of fibrosis using microrna-19b
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
DK2838512T3 (en) 2012-04-18 2018-11-19 Gruenenthal Gmbh MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
EP2846835B1 (en) 2012-05-11 2017-09-06 Grünenthal GmbH Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2014093711A1 (en) 2012-12-12 2014-06-19 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System Methods of treating hepatic fibrosis and associated diseases by regulating rev-erb activity
US9872851B2 (en) 2012-12-12 2018-01-23 The Charlotte-Mecklenburg Hospital Authority Methods of treating portal hypertension
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
AR096439A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido que contiene una o más partículas
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
US9879115B2 (en) * 2013-11-22 2018-01-30 Dow Global Technologies Llc Zinc catalyst/additive system for the polymerization of epoxide monomers
US9938374B2 (en) 2013-11-22 2018-04-10 Dow Global Technologies Llc Zinc catalyst/additive system for the polymerization of epoxide monomers
JP6122221B2 (ja) * 2013-11-22 2017-04-26 ダウ グローバル テクノロジーズ エルエルシー エポキシドモノマーの重合のための亜鉛触媒／添加剤システム
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
MX2016013542A (es) 2014-04-30 2017-02-14 Dow Global Technologies Llc Floculantes polimericos para el tratamiento de suspensiones minerales acuosas.
US11001512B2 (en) 2014-04-30 2021-05-11 Dow Global Technologies Llc Treatment of aqueous mineral suspensions with polymeric flocculants
EP3139909B1 (en) 2014-05-09 2025-01-01 Yale University Hyperbranched polyglycerol-coated particles
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
MX2016014738A (es) 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
CN106573210A (zh) 2014-07-31 2017-04-19 陶氏环球技术有限责任公司 用于对油砂细粒尾矿进行絮凝和脱水的管线内动态混合装置
JP2018517676A (ja) 2015-04-24 2018-07-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時放出および溶媒抽出に対する耐性を有する改変防止製剤
US10781117B2 (en) 2015-08-25 2020-09-22 Dow Global Technologies Llc Flocculation of high-solids mineral slurries
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
EP3416976A2 (en) 2016-02-16 2018-12-26 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
CA3014795A1 (en) 2016-02-16 2017-08-24 Yale University Compositions and methods for treatment of cystic fibrosis
AR108480A1 (es) 2016-05-27 2018-08-22 Dow Global Technologies Llc Método de tratamiento de suspensiones minerales con alto contenido de sólidos con floculantes poliméricos
WO2017207623A1 (en) 2016-05-31 2017-12-07 Université de Lausanne Mirna as biomarkers and regulators of cancer stem cells
WO2018005799A1 (en) 2016-06-29 2018-01-04 Georgia State University Research Foundation, Inc. Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
WO2018057325A1 (en) 2016-09-23 2018-03-29 Dow Global Technologies Llc Process for tailings remediation
US20210371316A1 (en) 2016-09-27 2021-12-02 Dow Global Technologies Llc Process for dewatering an aqueous process stream
US20210278390A1 (en) 2016-10-31 2021-09-09 Dow Global Technologies Llc Online analysis of oil sands tailings content
US20200113821A1 (en) 2017-04-04 2020-04-16 Yale University Compositions and methods for in utero delivery
CA3078827A1 (en) 2017-10-13 2019-04-18 Dow Global Technologies Llc Method to improve tailings flowability for pipeline transport
WO2019154884A1 (en) 2018-02-07 2019-08-15 Ecole Polytechnique Federale De Lausanne (Epfl) Method for determining cancer invasiveness and patient prognosis
CN117925571A (zh) 2018-10-19 2024-04-26 德克萨斯州大学系统董事会 工程化长散在元件（line）转座子及其使用方法
EP3677693A1 (en) 2019-01-03 2020-07-08 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Transpochimeric gene trancripts (tcgts) as cancer biomarkers
US20220372474A1 (en) 2019-06-21 2022-11-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
US20220243211A1 (en) 2019-06-21 2022-08-04 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
WO2021022161A1 (en) 2019-07-31 2021-02-04 Yale University Compositions and methods for treating sickle cell disease
WO2022237974A1 (en) 2021-05-12 2022-11-17 Ecole Polytechnique Federale De Lausanne (Epfl) Krab-containing zinc finger protein and cancer
WO2022261115A1 (en) 2021-06-07 2022-12-15 Yale University Peptide nucleic acids for spatiotemporal control of crispr-cas binding
JP2023043052A (ja) 2021-09-15 2023-03-28 住友精化株式会社 ポリアルキレンオキシドの製造方法
JP2023043054A (ja) 2021-09-15 2023-03-28 住友精化株式会社 ポリアルキレンオキシドの製造方法及びポリアルキレンオキシド
WO2024263649A1 (en) 2023-06-19 2024-12-26 Yale University Methods and compositions for enrichment and sequencing of expansion-specific rna transcripts
WO2025247961A1 (en) 2024-05-31 2025-12-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Lpa-lpar signaling as a therapeutic target or diagnostic tool for brain diseases
WO2026068747A1 (en) 2024-09-26 2026-04-02 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Astrocytic phosphoprotein (pea-15) for use in the treatment and/or prevention of a neuronal disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3385800A (en) * 1958-11-24 1968-05-28 Gen Tire & Rubber Co Polymerization of alkylene oxides by a catalyst system comprising organometallic compounds in combination with an oxygen-containing cocatalyst
DE1520983B2 (de) * 1961-03-14 1971-07-22 Takeda Chemical Industries Ltd , Osaka (Japan) Verfahren zur herstellung von alkylenoxydpolymeren
US3639267A (en) * 1969-12-19 1972-02-01 Hercules Inc Organozinc catalyst composition
JPS5035538B2 (enExample) * 1972-06-29 1975-11-17
JPS5831055B2 (ja) * 1976-08-26 1983-07-04 松下電器産業株式会社 テレビジヨン受像機のプログラム制御装置

Also Published As

Publication number Publication date
CA1279435C (en) 1991-01-22
US4667013A (en) 1987-05-19
BR8702151A (pt) 1988-02-09
EP0243969A2 (en) 1987-11-04
EP0243969A3 (en) 1988-10-05
JPS62273227A (ja) 1987-11-27
JPH0474370B2 (enExample) 1992-11-26

Similar Documents

Publication Publication Date Title
AU574309B2 (en) Catalyst for polyalkylene oxide
AU4704385A (en) Production of ethylene oxide
AU586048B2 (en) Silver catalyst for production of ethylene oxide and method for manufacture thereof
GB2193964B (en) Production of antibody catalysts
AU3869389A (en) Catalyst
AU560442B2 (en) Production of alkene oxides
EP0239071A3 (en) Production of composite oxide catalysts
AU7348787A (en) Catalysts for the production of alkylene oxides and their production
AU590115B2 (en) Catalyst preparation
AU6708486A (en) Oxidation of methane over heterogeneous catalysts
AU7249587A (en) Improved silver catalyst
GB8619284D0 (en) Hydrometallurgical production of zinc oxide
AU7407287A (en) Catalyst
AU584249B2 (en) Catalyst precursors
AU586260B2 (en) Partial oxidation process
AU7363287A (en) Synthesis of crystalline binary oxides
GB8714801D0 (en) Filtration of thick gluten
AU2156388A (en) Benzoxazinyl-triazole oxides, their production and use
AU6453586A (en) Catalyst precursors
AU6955687A (en) Cordierite precursor preparation
DE3566797D1 (en) Catalytic production of tert-amylphenols
AU580880B2 (en) Process for the preparation of a silver-containing catalyst
AU6256586A (en) Preparing nitrogen by catalytic reduction of nitrogen oxides
ZA865131B (en) Catalysts for the production of alkylene oxides
AU7677087A (en) Dipropargyloxybenzene compounds and their production